Investigators conducted a study to assess the incidence and risk factors associated with infective endocarditis in patients with and without active cancer.
In a Q&A, Asher Schranz, MD, MPH, discusses the importance of physician collaboration in the treatment of patients with drug use-associated infective endocarditis.
People with familial hypercholesterolemia with COVID-19 risk endothelial dysfunction. Therapy should continue during the course of the virus.
Researchers conducted a study that compared clinical outcomes and cost-effectiveness of 4 antibiotic treatment strategies for patients with drug-use associated infective endocarditis.
Researchers conducted a study to assess the effects of vancomycin plus ceftaroline for the treatment of patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.
Researchers sought to determine whether an infectious disease consultation improves clinical outcomes and increases treatment adherence in patients infected with Enterococcus species.
Researchers compared 90-day mortality and other clinical outcomes among patients with methicillin-susceptible Staphylococcus aureus infective endocarditis treated with cefazolin vs antistaphylococcal penicillins.
Researchers used a national cohort to describe the characteristics and clinical outcomes of maternity-associated infective endocarditis and to evaluate maternal and fetal outcomes of deliveries complicated by infective endocarditis.
A team of researchers propose that a population-based study of infective endocarditis in one county in Minnesota provides a unique opportunity to define temporal and seasonal variations in incidence over an extended period.
Researchers analyzed data from patients with a recent diagnosis of IE hospitalized to see whether PCT, proADM, and copeptin have prognostic value in IE compared with CRP, a known biomarker for IE.
